Bariatrics Clinical Trial - Celgene RPC01-3204

Status:

Open (Study open and enrolling)

ClinicalTrials.gov:

NCT03467958

CONDITION(S): Crohn Disease - TRIAL: Celgene RPC01-3204 - This is a Phase 3, open-label, multicenter extension study to evaluate safety and efficacy of ozanimod in subjects with moderately to severely active Crohn's Disease.An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Drug

Ozanimod

Trial Type

Interventional

Phase

Phase 3

Condition

Chron's Disease

Keywords

Weight loss | Bariatrics